Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Have Active Disease



Status:Recruiting
Conditions:Arthritis, Rheumatoid Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:18 - Any
Updated:12/5/2018
Start Date:December 2016
End Date:January 2020

Use our guide to learn which trials are right for you!

A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy

The purpose of this study is to determine how safe and effective the study drug Olokizumab
is, in patients with Rheumatoid Arthritis (RA) who are already receiving, but not fully
responding to treatment with an existing medication called a tumour necrosis factor alpha
inhibitor

The goal of this Phase III study is to assess the safety, tolerability, and efficacy of OKZ
in subjects with moderately to severely active RA who have responded inadequately to TNFi
therapy. The primary endpoint of the trial is at Week 12. Olokizumab is expected to reduce
the disease activity and improve physical function. The study is expected to provide safety
information in a large group of subjects over at least a 24 week period.

Inclusion Criteria:

Subjects may be enrolled in the study only if they meet all of the following criteria.

- Subjects willing and able to sign informed consent

- Subjects must have a diagnosis of adult onset RA classified by ACR/EULAR 2010 revised
classification criteria for RA for at least 24 weeks prior to Screening.

- Treatment with MTX for at least 12 weeks prior to Screening at a dose of 15 to 25
mg/week (or ≥10 mg/week if there is documented intolerance to higher doses)

- The dose and means of administering MTX must have been stable for at least 6
weeks prior to Screening.

- Subjects must be willing to take folic acid or equivalent throughout the study.

- Subjects must have moderately to severely active RA disease as defined by all of the
following:

- ≥6 tender joints (68 joint count) at Screening and baseline; and

- ≥6 swollen joints (66 joint count) at Screening and baseline; and

- CRP above ULN at Screening based on the central laboratory results.

- Subjects must have a documented inadequate response to treatment (i.e., TNFi failure)
with ≥1 licensed TNFi following at least 12 weeks of therapy with that agent.

Exclusion Criteria:

- Diagnosis of any other inflammatory arthritis or systemic rheumatic disease (e.g.,
gout, psoriatic or reactive arthritis, Crohn's disease, Lyme disease, juvenile
idiopathic arthritis, or systemic lupus erythematosus)

- Prior exposure to any licensed or investigational compound directly or indirectly
targeting IL 6 or IL 6R (including tofacitinib or other Janus kinases and spleen
tyrosine kinase [SYK] inhibitors)

- Prior treatment with cell depleting therapies including anti CD20 or investigational
agents (e.g., CAMPATH, anti CD4, anti CD5, anti CD3, and anti CD19) with the exception
of rituximab, which is allowed if it was discontinued at least 24 weeks prior to
baseline (rituximab should not be discontinued to facilitate a subject's participation
in the study, but should instead have been previously discontinued as part of a
subject's medical management of RA).

- Prior use of bDMARDs, within the following windows prior to baseline (bDMARDs should
not be discontinued to facilitate a subject's participation in the study, but should
instead have been previously discontinued as part of a subject's medical management of
RA):

1. 4 weeks for etanercept and anakinra

2. 8 weeks for infliximab

3. 10 weeks for adalimumab, certolizumab, and golimumab

4. 12 weeks for abatacept

- Use of oral glucocorticoids greater than 10 mg/day prednisone (or equivalent) or
change in dosage within 2 weeks prior to baseline

- Prior history of no response to hydroxychloroquine and sulfasalazine

- Prior use of cDMARDs (other than MTX) within the following windows prior to baseline
(cDMARDs should not be discontinued to facilitate a subject's participation in the
study, but should instead have been previously discontinued as part of a subject's
medical management of RA):

1. 4 weeks for sulfasalazine, azathioprine, cyclosporine, hydroxychloroquine,
chloroquine, gold, penicillamine, minocycline, or doxycycline

2. 12 weeks for leflunomide unless the subject has completed the following
elimination procedure at least 4 weeks prior to baseline: Cholestyramine at a
dosage of 8 grams 3 times daily for at least 24 hours, or activated charcoal at a
dosage of 50 grams 4 times daily for at least 24 hours

3. 24 weeks for cyclophosphamide

- Participation in any other investigational drug study within 30 days or 5 times the
terminal half-life of the investigational drug, whichever is longer, prior to baseline

- Other treatments for RA (e.g., Prosorba Device/Column) within 6 months prior to
baseline

- Use of non steroidal anti inflammatory drugs (NSAIDs) on unstable dose or switching of
NSAIDs within 2 weeks prior to baseline

- Previous participation in this study (randomized) or another study of OKZ

- Abnormal laboratory values

- Subjects with concurrent acute or chronic viral Hepatitis B or C infection

- Subjects with HIV infection

- Subjects with:

1. Current active TB disease or a history of active TB disease.

2. Close contact with an individual with active TB within 1.5yrs prior to Screening

3. History of untreated latent TB infection (LTBI), regardless of IGRA result at
Screening

4. Positive interferon-gamma release assay (IGRA) result at Screening. If
indeterminate, the IGRA can be repeated once during the Screening Period. If
there is a second indeterminate result, the subject will be excluded.

- Concurrent malignancy or a history of malignancy within the last 5 years

- History of chronic alcohol or drug abuse as judged by the Investigator

- Female subjects who are pregnant, currently lactating,

- Female subjects of childbearing who are not willing to use a highly effective method
of contraception during the study OR Male subjects with partners of childbearing
potential not willing to use a highly effective method of contraception during the
study.

- Subjects with a known hypersensitivity to any component of the OKZ drug product or
placebo

- Other exclusion criteria may apply
We found this trial at
66
sites
Albany, New York 12206
Principal Investigator: Joel Kremer
Phone: 518-489-4471
?
mi
from
Albany, NY
Click here to add this to my saved trials
1000 Alpine
Boulder, Colorado 80304
303-443-7229
Principal Investigator: Joseph Lutt
?
mi
from
Boulder, CO
Click here to add this to my saved trials
291 Campus Dr
Stanford, California 94305
(650) 725-3900
Principal Investigator: Mark Genovese
Phone: 650-498-4528
Stanford University School of Medicine Vast in both its physical scale and its impact on...
?
mi
from
Stanford, CA
Click here to add this to my saved trials
Albuquerque, New Mexico 87108
Principal Investigator: Michael McGuire
Phone: 505-348-9700
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Amarillo, Texas
Principal Investigator: Constantine Saadeh
Phone: 806-353-7000
?
mi
from
Amarillo, TX
Click here to add this to my saved trials
Austin, Texas 78731
Principal Investigator: Tina Bunch
Phone: 512-344-0362
?
mi
from
Austin, TX
Click here to add this to my saved trials
Bahia Blanca, Buenos Aires
Phone: +542914557273
?
mi
from
Bahia Blanca,
Click here to add this to my saved trials
Baytown, Texas 77521
Principal Investigator: Sabeen Najam
Phone: 832-672-7973
?
mi
from
Baytown, TX
Click here to add this to my saved trials
Boca Raton, Florida
Principal Investigator: Joseph Forstot
Phone: 561-361-6547
?
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Bowling Green, Kentucky 42101
Principal Investigator: Asad Fraser
Phone: 270-943-1302
?
mi
from
Bowling Green, KY
Click here to add this to my saved trials
Charleston, South Carolina 29406
Principal Investigator: William Edwards
Phone: 843-572-4840
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Chesapeake, Virginia 23320
Principal Investigator: Roger Lidman
Phone: 757-461-3400
?
mi
from
Chesapeake, VA
Click here to add this to my saved trials
Cincinnati, Ohio 45219
Principal Investigator: Michael Luggen
Phone: 513-559-2370
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Covina, California 91723
Principal Investigator: Samy Metyas
Phone: 626-869-5730
?
mi
from
Covina, CA
Click here to add this to my saved trials
Cumberland, Maryland 21502
Principal Investigator: Steven Klein
Phone: 301-724-4337
?
mi
from
Cumberland, MD
Click here to add this to my saved trials
Dayton, Ohio 45417
Principal Investigator: Sanford Wolfe
Phone: 937-223-4229
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Denver, Colorado 80230
Principal Investigator: Christopher Antolini
Phone: 303-394-2828
?
mi
from
Denver, CO
Click here to add this to my saved trials
El Cajon, California 92020
Principal Investigator: Arthur Mabaquiao
Phone: 619-334-4735
?
mi
from
El Cajon, CA
Click here to add this to my saved trials
Freehold, New Jersey 07728
Principal Investigator: Hisham El-Kadi
Phone: 732-780-7650
?
mi
from
Freehold, NJ
Click here to add this to my saved trials
2141 North Harbor Boulevard
Fullerton, California 92835
Principal Investigator: Jay Kim
Phone: 714-626-8623
?
mi
from
Fullerton, CA
Click here to add this to my saved trials
961 Smoky Mountain Springs # A
Gainesville, Georgia 30501
Principal Investigator: Marta Bognar
Phone: 770-531-3711
?
mi
from
Gainesville, GA
Click here to add this to my saved trials
Glendale, Arizona 85304
Principal Investigator: Saima Chohan
Phone: 480-443-8400
?
mi
from
Glendale, AZ
Click here to add this to my saved trials
Grapevine, Texas 76051
Principal Investigator: Dhiman Basu
Phone: 972-829-8839
?
mi
from
Grapevine, TX
Click here to add this to my saved trials
Greensboro, North Carolina 27408
Principal Investigator: Nilamadhab Mishra
Phone: 336-763-6968
?
mi
from
Greensboro, NC
Click here to add this to my saved trials
Hagerstown, Maryland 21740
Principal Investigator: Mary Howell
Phone: 301-714-1506
?
mi
from
Hagerstown, MD
Click here to add this to my saved trials
Hemet, California 92453
Principal Investigator: Chandrakant Mehta
Phone: 951-652-5000
?
mi
from
Hemet, CA
Click here to add this to my saved trials
Hot Springs, Arkansas 71913
Principal Investigator: Ratinder Kaur
Phone: 501-627-1800
?
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Houston, Texas 77004
Principal Investigator: Samuel Pegram
Phone: 713-521-7865
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77004
Principal Investigator: Jacqueline Vo
Phone: 713-640-5477
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas
Principal Investigator: Philip Waller
Phone: 281-240-1045
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77098
Principal Investigator: Asif Cochinwala
Phone: 713-333-9323
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77070
Principal Investigator: Qaiser Rehman
Phone: 281-517-0550
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77024
Principal Investigator: Dale Halter
Phone: 713-988-2615
?
mi
from
Houston, TX
Click here to add this to my saved trials
Huntsville, Alabama 35801
Principal Investigator: William Shergy
Phone: 256-704-7098
?
mi
from
Huntsville, AL
Click here to add this to my saved trials
Idaho Falls, Idaho 83404
Principal Investigator: Craig Scoville
Phone: 208-542-9080
?
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
Kalispell, Montana 59901
Principal Investigator: Roger Diegel
Phone: 406-755-1460
?
mi
from
Kalispell, MT
Click here to add this to my saved trials
Kansas City, Kansas
Principal Investigator: Herbert Lindsley
Phone: 913-588-6009
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
Lakewood, California 90712
Principal Investigator: Gerald Ho
Phone: 562-867-8195
?
mi
from
Lakewood, CA
Click here to add this to my saved trials
1003 Olde Waterford Way
Leland, North Carolina 28451
Principal Investigator: David Snow
Phone: 608-848-8900
?
mi
from
Leland, NC
Click here to add this to my saved trials
Little Rock, Arkansas 72205
Principal Investigator: Lue Cummins
Phone: 501-223-4590
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Lubbock, Texas 79424
Principal Investigator: Jitendra Vasandani
Phone: 806-993-1040
?
mi
from
Lubbock, TX
Click here to add this to my saved trials
Meridian, Idaho 83642
Principal Investigator: Mark Turner
Phone: 208-377-8659
?
mi
from
Meridian, ID
Click here to add this to my saved trials
Miami, Florida 33135
Principal Investigator: Mark Kutner
Phone: 305-631-6704
?
mi
from
Miami, FL
Click here to add this to my saved trials
101 3rd Avenue Southwest
Minot, North Dakota 58701
Principal Investigator: Erdal Diri
Phone: 701-857-2510
?
mi
from
Minot, ND
Click here to add this to my saved trials
Monroe, Louisiana 71203
Principal Investigator: Jyothi Mallepalli
Phone: 318-388-5830
?
mi
from
Monroe, LA
Click here to add this to my saved trials
Nassau Bay, Texas 77058
Principal Investigator: Prashanth Sunkureddi
Phone: 713-677-0086
?
mi
from
Nassau Bay, TX
Click here to add this to my saved trials
New York, New York 10065
Principal Investigator: David Goddard
Phone: 929-455-2399
?
mi
from
New York, NY
Click here to add this to my saved trials
Newark, Delaware 19713
Principal Investigator: Sheerin Javed
Phone: 302-633-9033
?
mi
from
Newark, DE
Click here to add this to my saved trials
Omaha, Nebraska 68114
Principal Investigator: William Palmer
Phone: 402-934-1666
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Orlando, Florida 32804
Principal Investigator: Kwabena Ayesu
Phone: 407-271-8030
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Owensboro, Kentucky 42303
Principal Investigator: David Johnson
Phone: 270-691-1827
?
mi
from
Owensboro, KY
Click here to add this to my saved trials
Pembroke Pines, Florida 33026
Principal Investigator: Jeanne-Elyse Cedeno
Phone: 954-842-3147
?
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Perrysburg, Ohio 43551
Principal Investigator: Edward Goldberger
Phone: 419-873-1532
?
mi
from
Perrysburg, OH
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19152
Principal Investigator: James Udell
Phone: 215-725-1710
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
7117 Brockton Avenue
Riverside, California 92506
Principal Investigator: Andre Babajanians
Phone: 951-321-6473
?
mi
from
Riverside, CA
Click here to add this to my saved trials
San Antonio, Texas 78240
Principal Investigator: Alex De Jesus
Phone: 210-762-6577
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
San Leandro, California 94578
Principal Investigator: Clark Neuwelt
Phone: 510-357-1303
?
mi
from
San Leandro, CA
Click here to add this to my saved trials
Santa Monica, California 90404
Principal Investigator: Orrin Troum
Phone: 310-449-1999
?
mi
from
Santa Monica, CA
Click here to add this to my saved trials
South Charleston, West Virginia 25309
Principal Investigator: Suzanne Gharib
Phone: 304-389-4455
?
mi
from
South Charleston, WV
Click here to add this to my saved trials
Tampa, Florida 33613
Principal Investigator: Harris McIlwain
Phone: 813-345-2393
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Upland, California 91786
Principal Investigator: Eric Lee
Phone: 909-296-8700
?
mi
from
Upland, CA
Click here to add this to my saved trials
Wheaton, Maryland 20902
Principal Investigator: Herbert Baraf
Phone: 301-942-6610
?
mi
from
Wheaton, MD
Click here to add this to my saved trials
Whittier, California 90606
?
mi
from
Whittier, CA
Click here to add this to my saved trials
Wilmington, North Carolina 28401
Principal Investigator: Mark Harris
Phone: 910-762-1182
?
mi
from
Wilmington, NC
Click here to add this to my saved trials
10857 Kuykendahl Road
Woodville, Texas 77382
Principal Investigator: Tamar Brionez
Phone: 832-452-7249
?
mi
from
Woodville, TX
Click here to add this to my saved trials
Worcester, Massachusetts 01610
Principal Investigator: Charles Birbara
Phone: 508-755-0201
?
mi
from
Worcester, MA
Click here to add this to my saved trials